CME Group reports FY 2025 market data revenue of USD 0.80 billion, up 13%

Reuters
02/04
CME Group reports FY 2025 market data revenue of USD 0.80 billion, up 13%

CME Group reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For FY 2025, the company posted total revenue of USD 6.52 billion, marking a 6% increase. Operating income for the year was USD 4.20 billion. Net income reached USD 4.10 billion, with diluted earnings per share at USD 11.16. On an adjusted basis, net income was USD 4.09 billion and diluted earnings per share were USD 11.20. For Q4 2025, CME Group recorded revenue of USD 1.65 billion and operating income of USD 1.00 billion. Net income for the quarter was USD 1.20 billion, with diluted earnings per share of USD 3.24. Adjusted net income for Q4 was USD 1.01 billion, while adjusted diluted earnings per share stood at USD 2.77. CME Group achieved record annual market data revenue of USD 803 million, up 13% for the year. The company reported record average daily volume of 28.1 million contracts in 2025, with commodities trading volume growing 12% and financials trading volume rising 5%. In Q4, CME Group delivered its second-highest quarterly revenue and the highest Q4 volume on record, according to Chairman and CEO Terry Duffy, who attributed the performance to continued strong client demand in a "risk-always-on environment."

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CME Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: AQ78236) on February 04, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10